Our medical solutions
Early detection and precise disease monitoring
Early Detection
Our cutting-edge blood-based diagnostic platform identifies Multiple Sclerosis (MS) at its earliest stages, enabling timely intervention before significant neurological damage occurs. By leveraging AI-driven biomarker analysis, we offer a non-invasive, highly accurate alternative to traditional diagnostic methods like MRI and lumbar punctures, reducing delays and uncertainty in diagnosis.
Progression Prediction
Beyond early detection, our technology provides deep insights into disease progression, helping clinicians monitor MS activity over time. By analyzing key biomarkers and AI-powered predictive models, we can assess disease trajectory, detect flare-ups, and support personalized treatment adjustments, ensuring better long-term management for patients.
Driven by Innovation, Committed to Impact
Our multidisciplinary team—comprising leading researchers, clinicians, and biotech innovators—is dedicated to transforming cutting-edge science into real-world diagnostic solutions. By combining expertise in proteomics, AI-driven biomarker discovery, and clinical neurology, we are revolutionizing disease detection and management, making diagnostics faster, more accessible, and patient-centric.
Faster, Easier, and More Accurate Disease Detection
Our innovative approach integrates proteomics, AI-driven biomarker discovery, and rigorous clinical validation to deliver faster, more accessible, and non-invasive diagnostic solutions.
Copyright Proheme 2021